This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Badros, A. Articles by Tricot, G. Search for Related Content PubMed PubMed Citation Articles by Badros, A. Articles by Tricot, G. Social Bookmarking                            What's this?

Improved Outcome of Allogeneic Transplantation in High-Risk Multiple Myeloma Patients After Nonmyeloablative Conditioning

From the Myeloma and Transplantation Research Center, University of Arkansas for Medical Sciences, Little Rock, AR.

Address reprint requests to Ashraf Badros, MD, University of Maryland, Greenebaum Cancer Center, 22 South Greene St, Baltimore, MD 21201; email: abadros{at}umm.edu

PURPOSE: We present our experience with relapsed and recently diagnosed patients with high-risk multiple myeloma (MM) receiving immunosuppressive, nonmyeloablative melphalan (MEL)-based conditioning regimens (mini-allograft).

PATIENTS AND METHODS: Thirty-one MM patients received allografts from HLA-matched siblings (n = 25) or unrelated donors (n = 6) using a mini-allograft. Seventeen had progressive disease (PD) and 14 had responsive disease (RD) (six with primary RD and eight with responsive relapse). Thirty patients had received one (n = 13) or two or more (n = 17) prior autologous transplantations (ATs). Median age was 56 years (range, 38 to 69 years). Twenty-one patients had chromosome 13 abnormality. Two patients were hemodialysis dependent. Blood and bone marrow grafts were administered to 28 and three patients, respectively. Donor lymphocyte infusions were given to 18 patients either to attain full donor chimerism (n = 6) or to eradicate residual disease (n = 12).

RESULTS: By day 100, 25 (89%) of 28 patients were full donor chimeras, one was a mixed chimera, and two had autologous reconstitution. Acute graft-versus-host disease (GVHD) developed in 18 patients (58%), and 10 progressed to chronic GVHD (limited in six and extensive in four). At a median follow-up of 6 months, 19 (61%) of 31 patients achieved complete/near complete remission. Twelve patients (39%) have died: three of PD, three of early treatment-related mortality (TRM) (before day 100), and six of late TRM. Median overall survival (OS) was 15 months. At 1 year, there was a significantly longer event-free survival (86% v 31%, P = .01) and OS (86% v 48%, P = .04) when a mini-allograft was performed after one versus two or more prior ATs, respectively. When compared with historical MM controls (n = 93) receiving conventional allografts, early TRM was significantly lower (10% v 29%, P = .03), and OS at 1 year was better (71% v 45%; P = .08) in the mini-allograft MM patients.

CONCLUSION: Mini-allograft induced excellent disease control in MM patients with high-risk disease, but is still associated with a significant GVHD.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				J.-H. Bourhis, Y. Bouko, S. Koscielny, M. Bakkus, H. Greinix, G. Derigs, G. Salles, W. Feremans, J. Apperley, D. Samson, et al. Relapse risk after autologous transplantation in patients with newly diagnosed myeloma is not related with infused tumor cell load and the outcome is not improved by CD34+ cell selection: long term follow-up of an EBMT phase III randomized study Haematologica, August 1, 2007; 92(8): 1083 - 1090. [Abstract] [Full Text] [PDF]

				R. M. Saliba, M. de Lima, S. Giralt, B. Andersson, I. F. Khouri, C. Hosing, S. Ghosh, J. Neumann, Y. Hsu, J. De Jesus, et al. Hyperacute GVHD: risk factors, outcomes, and clinical implications Blood, April 1, 2007; 109(7): 2751 - 2758. [Abstract] [Full Text] [PDF]

				M. Attal, P. Moreau, H. Avet-Loiseau, and J.-L. Harousseau Stem Cell Transplantation in Multiple Myeloma Hematology, January 1, 2007; 2007(1): 311 - 316. [Abstract] [Full Text] [PDF]

				A. Geffroy-Luseau, A. Moreau-Aubry, R. Bataille, and C. Pellat-Deceunynck Allogeneic T lymphocytes as a source of peptide-dependent T cells specific for myeloma cells Int. Immunol., September 1, 2005; 17(9): 1193 - 1200. [Abstract] [Full Text] [PDF]

				C. Crawley, M. Lalancette, R. Szydlo, M. Gilleece, K. Peggs, S. Mackinnon, G. Juliusson, L. Ahlberg, A. Nagler, A. Shimoni, et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT Blood, June 1, 2005; 105(11): 4532 - 4539. [Abstract] [Full Text] [PDF]

				M. S. Raab, F. W. Cremer, I. N. Breitkreutz, S. Gerull, T. Luft, A. Benner, M. Goerner, A. D. Ho, H. Goldschmidt, and M. Moos Molecular monitoring of tumour load kinetics predicts disease progression after non-myeloablative allogeneic stem cell transplantation in multiple myeloma Ann. Onc., April 1, 2005; 16(4): 611 - 617. [Abstract] [Full Text] [PDF]

				R. Diaconescu, C. R. Flowers, B. Storer, M. L. Sorror, M. B. Maris, D. G. Maloney, B. M. Sandmaier, and R. Storb Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors Blood, September 1, 2004; 104(5): 1550 - 1558. [Abstract] [Full Text] [PDF]

				M. L. Sorror, M. B. Maris, B. Storer, B. M. Sandmaier, R. Diaconescu, C. Flowers, D. G. Maloney, and R. Storb Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities Blood, August 15, 2004; 104(4): 961 - 968. [Abstract] [Full Text] [PDF]

				N. Kroger, G. Schilling, H. Einsele, P. Liebisch, A. Shimoni, A. Nagler, J. A. Perez-Simon, J. F. San Miguel, M. Kiehl, A. Fauser, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation Blood, June 1, 2004; 103(11): 4056 - 4061. [Abstract] [Full Text] [PDF]

				J. Casper, W. Knauf, T. Kiefer, D. Wolff, B. Steiner, U. Hammer, R. Wegener, H.-D. Kleine, S. Wilhelm, A. Knopp, et al. Treosulfan and fludarabine: a new toxicity-reduced conditioning regimen for allogeneic hematopoietic stem cell transplantation Blood, January 15, 2004; 103(2): 725 - 731. [Abstract] [Full Text] [PDF]

				J.-L. Harousseau, J. Shaughnessy Jr., and P. Richardson Multiple Myeloma Hematology, January 1, 2004; 2004(1): 237 - 256. [Abstract] [Full Text] [PDF]

				B. Barlogie, J. Shaughnessy, G. Tricot, J. Jacobson, M. Zangari, E. Anaissie, R. Walker, and J. Crowley Treatment of multiple myeloma Blood, January 1, 2004; 103(1): 20 - 32. [Abstract] [Full Text] [PDF]

				M. Zoller Tumor Vaccination after Allogeneic Bone Marrow Cell Reconstitution of the Nonmyeloablatively Conditioned Tumor-Bearing Murine Host J. Immunol., December 15, 2003; 171(12): 6941 - 6953. [Abstract] [Full Text] [PDF]

				J. Blade, D. H. Vesole, and M. Gertz Transplantation for multiple myeloma: who, when, how often? Blood, November 15, 2003; 102(10): 3469 - 3477. [Full Text] [PDF]

				D. H. Vesole "Full length, midi, or mini": a fashion statement for transplants in myeloma Blood, November 1, 2003; 102(9): 3081 - 3082. [Full Text] [PDF]

				D. G. Maloney, A. J. Molina, F. Sahebi, K. E. Stockerl-Goldstein, B. M. Sandmaier, W. Bensinger, B. Storer, U. Hegenbart, G. Somlo, T. Chauncey, et al. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma Blood, November 1, 2003; 102(9): 3447 - 3454. [Abstract] [Full Text] [PDF]

				P. Corradini, M. Cavo, H. Lokhorst, G. Martinelli, C. Terragna, I. Majolino, P. Valagussa, M. Boccadoro, D. Samson, A. Bacigalupo, et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma Blood, September 1, 2003; 102(5): 1927 - 1929. [Abstract] [Full Text] [PDF]

				S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot Advances in Biology and Therapy of Multiple Myeloma Hematology, January 1, 2003; 2003(1): 248 - 278. [Abstract] [Full Text] [PDF]

				N. Kroger, H. G. Sayer, R. Schwerdtfeger, M. Kiehl, A. Nagler, H. Renges, T. Zabelina, B. Fehse, F. Ayuk, G. Wittkowsky, et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality Blood, December 1, 2002; 100(12): 3919 - 3924. [Abstract] [Full Text] [PDF]

				K. S. Peggs, S. Mackinnon, K. Yong, and A. Badros Reduced Intensity Conditioning and Allogeneic Stem-Cell Transplantation: Determining Its Role in Multiple Myeloma J. Clin. Oncol., October 15, 2002; 20(20): 4268 - 4269. [Full Text] [PDF]

				K. Branson, R. Chopra, P. D. Kottaridis, G. McQuaker, A. Parker, S. Schey, R. K. Chakraverty, C. Craddock, D. W. Milligan, R. Pettengell, et al. Role of Nonmyeloablative Allogeneic Stem-Cell Transplantation After Failure of Autologous Transplantation in Patients With Lymphoproliferative Malignancies J. Clin. Oncol., October 1, 2002; 20(19): 4022 - 4031. [Abstract] [Full Text] [PDF]

				S. V. Rajkumar, M. A. Gertz, R. A. Kyle, P. R. Greipp, and Mayo Clinic Myeloma, Amyloid, and Dysproteinemia G Current Therapy for Multiple Myeloma Mayo Clin. Proc., August 1, 2002; 77(8): 813 - 822. [Abstract] [PDF]

				K. C. Anderson, J. D. Shaughnessy Jr., B. Barlogie, J.-L. Harousseau, and G. D. Roodman Multiple Myeloma Hematology, January 1, 2002; 2002(1): 214 - 240. [Abstract] [Full Text]

				D. G. Maloney, B. M. Sandmaier, S. Mackinnon, and J. A. Shizuru Non-Myeloablative Transplantation Hematology, January 1, 2002; 2002(1): 392 - 421. [Abstract] [Full Text]